Results 101 to 110 of about 24,384 (198)

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Transfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone‐Junior, José Bordin, Langhi Dante, Carla Dinardo   +11 more
wiley   +1 more source

Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects [PDF]

, 2017
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL).
Gabčová, Gabriela, Gajdoš, Petr, Kriegová, Eva, Kudělka, Miloš, Manukyan, Gayane, Mikulková, Zuzana, Papajík, Tomáš, Procházka, Vít, Ryznerová, Pavlína, Turcsányi, Peter, Urbanová, Renata   +10 more
core   +1 more source

Histiocytes: Multifaceted Regulators of Health and Disease

Veterinary Clinical Pathology, EarlyView.
ABSTRACT The mononuclear phagocyte system encompasses macrophages, dendritic cells (DCs), and monocytes. Tissue‐resident macrophages and dendritic cells arise during embryogenesis and are replenished either through self‐renewal or by monocytes during inflammation.
Erika J. Gruber
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, Volume 20, Issue 5, Page 1220-1236, May 2026.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

Frontiers in Immunology, 2017
For many years, disappointing results have been generated by many investigations, which have utilized a variety of immunologic strategies to enhance the ability of a patient’s immune system to recognize and eliminate malignant cells.
Giuseppe Sconocchia, Sara Caratelli, Tommaso Sconocchia, Roberto Arriga, Andrea Coppola, Giulia Lanzilli, Davide Lauro, Adriano Venditti, Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Soldano Ferrone   +11 more
doaj   +1 more source

Biological responses to spider silk - antibiotic fusion protein [PDF]

, 2012
The development of a new generation of multifunctional biomaterials is a continual goal for the field of materials science. The in vivo functional behaviour of a new fusion protein that combines the mechanical properties of spider silk with the ...
Aarbiou, Aarbiou, Alba-Loureiro, Allmeling, Allmeling, Amersfoort, Bai, Bala, Bals, Baoyong, Beek, Bendelac, Bessa, Beutner, Bini, Bowers, Campoccia, Chao, Chavakis, Chung, Clevers, Falzacappa, Ganz, Ganz, Gomes, Gomes, Grigat, Hardy, Haskó, Hayashi, Heim, Hiemstra, Huang, Huang, Hubbell, Janeway, Janmey, Jenkins, Kilian, Kirker-Head, Koliaraki, Krause, Kuijpers, Kuijpers, Langer, LeBien, Lü, Mahoney, Meinel, Mishra, Murphy, Nemeth, Nemeth, Numata, Omenetto, Pabbruwe, Park, Park, Pigeon, Rabotyagova, Rohde, Romano, Ruiz, Scheibel, Schierholz, Schütt, Singh, Spiess, Sponner, Tang, Tecle, Vyoral, Wallace, Widhe, Xiaa, Xu, Yan, Zhang, Zhu   +78 more
core   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1134-1144, May 2026.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Differential binding patterns of anti-sulfatide antibodies to glial membranes [PDF]

, 2018
Sulfatide is a major glycosphingolipid in myelin and a target for autoantibodies in autoimmune neuropathies. However neuropathy disease models have not been widely established, in part because currently available monoclonal antibodies to sulfatide may ...
Barrie, Jennifer A., Cunningham, Madeleine E., Gourlay, Dawn, Halstead, Susan K., McGonigal, Rhona, Meehan, Gavin R., Wang, Yuzhong, Willison, Hugh J., Yao, Denggao   +8 more
core   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source

COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement

Frontiers in Immunology
BackgroundSARS-CoV-2 infection and COVID-19 vaccination can induce antibodies that cross-react with dengue virus (DENV). Pre-existing IgG antibodies against DENV are known to enhance infection through antibody-dependent enhancement (ADE) via Fcγ ...
Sebastian Reinig, Chin Kuo, Sheng-Yu Huang, Kuei-Ching Hsiung, Kuei-Ching Hsiung, Po-Kai Chen, Etsuro Ito, Etsuro Ito, Etsuro Ito, Ing-Kit Lee, Ing-Kit Lee, Ching-Yen Tsai, Shu-Min Lin, Shu-Min Lin, Shin-Ru Shih, Shin-Ru Shih   +15 more
doaj   +1 more source